Researchers have recently uncovered a new virus called HKU5-CoV-2 that has the ability to enter human cells in a similar manner to the virus responsible for COVID-19. This virus, however, is not as efficient at entering cells as COVID-19, leading experts to caution against overhyping these findings.
The Wuhan Institute of Virology in China detailed their discovery of HKU5-CoV-2 and potential treatments for infections in a recent publication in the journal Cell. This virus, found in bats, belongs to the coronavirus family, a group of pathogens that can impact both mammals and birds. Some coronaviruses have the potential to jump from animals to humans, as seen with SARS-CoV-2.
In their study, researchers examined how HKU5-CoV-2 interacts with human cells by testing it in laboratory settings and models of the human digestive system and respiratory tract. They discovered that the virus’s spike protein can bind to the membrane of human cells through a receptor enzyme on the cell surface, facilitated by a feature known as a “furin cleavage site.”
While HKU5-CoV-2 shares similarities in its transmission pathway with SARS-CoV-2, it is not as adept at infecting human cells. Despite showing some adaptation to human cells, the virus struggled to bind to them effectively. Scientists have emphasized the need for caution regarding the potential threat posed by HKU5-CoV-2, with the researchers themselves warning against exaggerating the risk of its emergence in human populations.
Dr. Michael Osterholm, an infectious disease expert at the University of Minnesota, expressed concerns over the sensationalized reaction to the research, suggesting that existing immunity to similar viruses could offer protection against a potential pandemic. Nevertheless, the news of the discovery has sparked increased interest in vaccine manufacturers, with shares of companies like Pfizer, Moderna, and Novovax rising following the announcement.
In the event of a human infection with a bat virus like HKU5-CoV-2, researchers suggest that treatments such as monoclonal antibodies and antiviral drugs could be effective. Antiviral drugs work by inhibiting the spread of the virus in the body, potentially alleviating symptoms and reducing the duration of illness. Monoclonal antibodies, on the other hand, are lab-made proteins designed to target various diseases, including cancer and viral infections like COVID-19.
While monoclonal antibodies have shown promise in treating COVID-19, their effectiveness can vary depending on the virus variant. As such, researchers have had to develop new treatments quickly to keep pace with the evolving nature of the virus. These treatment options could play a crucial role in combating potential future outbreaks of bat-borne viruses like HKU5-CoV-2.
